FDA Approves Iberdomide Combo for Relapsed or Refractory Multiple Myeloma

AIMode News Desk · curated summary

August 14, 20261 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: FDA Approves Iberdomide Combo for Relapsed or Refractory Multiple Myeloma Medscape

About this story

This story was aggregated from Medscape. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

For agents:JSON record OpenAPI WebMCP llms.txt

FDA Approves Iberdomide Combo for Relapsed or Refractory Multiple Myeloma

About this story

More in Health

NEWSLETTER: Experimental blood test finds high-risk colorectal lesions before cancer develops

Cancer research needs sustainable funding from New Jersey, advocates say

FDA Approves Iberdomide Plus Daratumumab and Dexamethasone for Multiple Myeloma

That Sugar in Your Soda? Scientists Are Taking a Closer Look at Its Links to Cancer